Symptomatic Acute Myopericarditis after Pfizer Vaccine against COVID-19

Ivana Tabalipa Giublin,1,2 Camila Hartmann,1,4 Otavio Celeste Mangili,1,5 Alfredo Akio Shiozaki,4 Lidia Ana Zytrynski Moura1,2

Hospital Marcelino Champagnat,1 Curitiba, PR – Brazil Pontifícia Universidade Católica do Paraná (PUCPR),2 Curitiba, PR – Brazil Professor Associado de Cardiologia da Uninga,2 Maringá, PR – Brazil Centro de Diagnósticos Hospital Paraná (Unitom/DASA),3 Maringá, PR – Brazil

Introduction

Cases of myocarditis and pericarditis have been reported in diverse parts of the world since vaccination against the new coronavirus began with messenger RNA (mRNA) vaccines, mainly those produced by Pfizer-BioNTech.1 The pathophysiology of this vaccine-induced pathology is not yet fully understood, but it may be related to the active component of the vaccine (the mRNA sequence that encodes the SARS-CoV-2 spike protein) or to the immune system response that is triggered after vaccination2. What is known so far is that it is a rare adverse event in view of the number of people who have already been immunized with these components, and the vast majority of cases reported in the literature have a benign course, with good evolution.1,10 We report a case of myopericarditis in a young adult who presented symptoms 2 days after receiving the second dose of the Pfizer vaccine against COVID-19.

Case Report

JASD, a male, 18-year-old patient, with a history of leukemia treated in childhood, developed intense chest pain, radiating to the left upper limb, as well as back pain, 2 days after receiving the second dose of the Pfizer vaccine against COVID-19. Upon hospitalization for investigation in his hometown, his electrocardiogram showed ST-segment elevation in the inferolateral wall, and there were changes in troponin I levels (6.33; reference value: 0 to 0.5) and CK-MB mass (98.4; reference value: 0 to 7.0). Electrocardiogram showed changes in ventricular repolarization in the inferior wall and slow progression of the R wave, as well as ST-segment elevation in the anterior wall. The transthoracic echocardiogram was normal. The patient had transient episodes of pulmonary congestion, bradycardia, and elevated lactate levels, but all of these were easy to manage and resolve. He did not have any new episodes of chest pain after admission to this hospital, and he evolved with a drop in C-reactive protein and troponin I. After completing pulse therapy with corticosteroids for a 3-day period, resonance imaging was repeated to reassess the extent of injury, which showed improvement in relation to the last exam that had been performed in his hometown. The patient evolved with clinical stability and significant improvement. He was discharged after 6 days, with a prescription for bisoprolol, enalapril, spironolactone, and colchicine. He was further instructed to avoid physical exertion for a minimum period of 6 months, to undergo outpatient Holter, and to return early to the assistant cardiologist in his hometown.

Keywords

Myocarditis; Pericarditis; COVID-19 Vaccines

Mailing Address: Ivana Tabalipa Giublin • Avenida Presidente Afonso Camargo, 1.399. Postal Code 80050-370, Cristo Rei, Curitiba, PR - Brazil E-mail: ivanagiublin@gmail.com Manuscript received January 21, 2022, revised manuscript February 01, 2022, accepted February 22, 2022

DOI: https://doi.org/10.36660/abchf.20220023
Discussion

Repeated case descriptions seem to suggest a new adverse event associated with mRNA vaccines, namely, post-vaccination myocarditis and pericarditis, which had not been observed in the initial studies published by the pharmaceutical company in December 2020. The occurrence seems to be more common in young male adults. In the initial clinical trials of mRNA vaccines, systemic adverse reactions were also observed more frequently in this population, probably due to increased immunogenicity. A systematic review that evaluated cardiac complications in this scenario, including 43 case reports and 26 series, identified that myocarditis/myopericarditis and pericarditis were the most common adverse events among the 243 complications reported, and they were observed more after the Pfizer mRNA vaccine. The majority of patients are previously healthy, and the symptoms are typical of myocarditis and pericarditis due to other causes, with chest pain being the most reported symptom, followed by fever. They generally start within a week of the second dose of the vaccine. Electrocardiographic changes (such as ST-segment changes) are present in the vast majority of cases, as are increased troponin and increased inflammatory markers (such as C-reactive protein and erythrocyte sedimentation rate). The type of troponin used has been heterogeneous among the studies. A transthoracic echocardiogram with a normal result was common in several reports, but there were always changes on cardiac resonance imaging (in most cases, late enhancement with gadolinium, indicating myocardial necrosis/fibrosis). Before concluding diagnosis of post-vaccination myocarditis, the vast majority of patients underwent other exams to rule out other etiologies, including infection caused by the novel coronavirus. The most common situation is that patients present a mild condition with rapid recovery and short length of hospital stay. As pharmacological treatment, they receive doses of non-steroidal anti-inflammatory drugs, colchicine, and corticosteroids. Some patients require intravenous immunoglobulin, acetylsalicylic acid, beta-blockers, and angiotensin-converting enzyme inhibitors due to left ventricular systolic dysfunction. Most of the clinical information available on myocarditis after mRNA vaccination has been published in the form of case reports and series, making further studies necessary in order to establish these patients’ long-term prognosis.

Conclusion

Although reports of myocarditis and pericarditis related to mRNA vaccines are becoming increasingly frequent in the literature, they are still considered rare in view of the number of individuals who are receiving these vaccines. Furthermore, the majority of cases have had a quick recovery, with good clinical evolution. Therefore, in spite of the real possibility of post-vaccination myocarditis, it is
still recommended to maintain the immunization schedule as a strategy to face the pandemic, seeing that the benefits of vaccination continue to outweigh the risks.

Acknowledgements
The authors would like to thank Dr. Otavio Celeste Mangili for referring the patient and the rest of the assisting team that accompanied the patient in Maringá, Paraná, Brazil. Thanks to the members of the Cardiac Intensive Care Unit at Hospital Marcelino Champagnat for providing medical services to the community and contributing to the development of a service of excellence. The authors would also like to thank the team responsible for admissions to the ward for working together on behalf of patients. Special thanks to the patients who place their trust in the hospital’s multidisciplinary team, to take care of their health, making continuous improvement possible.

Author Contributions
Conception and design of the study, data acquisition, manuscript drafting: Giublin IT; critical revision for important intellectual content: Hartmann C, Moura LAZ; supervision as principal investigator: Mangili OC, Shiozaki AA, Moura LAZ.

Potential Conflicts of Interest
The authors declare no relevant conflicts of interest.

Sources of Funding
There were no external funding sources for this study.

Academic Affiliation
This study is not affiliated with any postgraduate programs.

Ethical Approval and Informed Consent
This article does not contain human or animal studies conducted by any of the authors.

References